Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

This study has been completed.
MacuSight, Inc.
Information provided by (Responsible Party):
Santen Inc. Identifier:
First received: April 4, 2008
Last updated: January 8, 2013
Last verified: July 2010
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.

Condition Intervention Phase
Diabetic Macular Edema
Drug: Sirolimus
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Resource links provided by NLM:

Further study details as provided by Santen Inc.:

Primary Outcome Measures:
  • Best-corrected visual acuity by ETDRS [ Time Frame: 180 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Foveal central subfield thickness as determined by OCT [ Time Frame: 180 days ] [ Designated as safety issue: No ]
  • Safety across dose groups versus placebo [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]

Enrollment: 131
Study Start Date: June 2008
Study Completion Date: May 2012
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Sirolimus
Two subconjunctival injections of 220 micrograms sirolimus each.
Other Name: MS-R003, rapamycin
Experimental: 2 Drug: Sirolimus
Two subconjunctival injections of 440 micrograms sirolimus each.
Other Name: MS-R001, rapamycin
Experimental: 3 Drug: Sirolimus
Two subconjunctival injections of 880 micrograms sirolimus each.
Other Name: MS-R002, rapamycin
Placebo Comparator: 4 Drug: Placebo
Two subconjunctival injections of placebo.
Other Name: Vehicle


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria include but are not limited to:

  • Diagnosed with diabetes mellitus
  • Macular edema secondary to diabetic retinopathy
  • Visual acuity of 20/40 to 20/200 in study eye

Exclusion Criteria include but are not limited to:

  • Any other ocular disease that could compromise vision in the study eye
  • Any of the following treatments to the study eye within 90 days prior to study start: intravitreal injections; posterior subtenons steroids; focal/grid macular photocoagulation; intraocular surgery
  • Capsulotomy of the study eye within 30 days prior to study start
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00656643

United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85014
Sponsors and Collaborators
Santen Inc.
MacuSight, Inc.
Study Director: Joel Naor, MD MacuSight, Inc.
  More Information

Responsible Party: Santen Inc. Identifier: NCT00656643     History of Changes
Other Study ID Numbers: DR-002 
Study First Received: April 4, 2008
Last Updated: January 8, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Macular Edema
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Physiological Effects of Drugs processed this record on May 26, 2016